Developed more than 10 years ago, the first companion diagnostic for Herceptin, changed the way doctors approached treatment on their patients with breast cancer. Today, the companion diagnostics industry continues to develop innovative testing that can predict the likelihood that a single therapeutic will or will not be an effective therapeutic.
CMCD works with clinicians and their patients utilizing these tests to help ensure the most appropriate treatment that works with each individual’s genetic makeup. These tests help our partners increase effectiveness, lower costs and provide a safer, more personalized treatment for their patients.
Our offerings include companion diagnostics, used in the treatment and care of cancer patients, as well as Pharmacogenetics testing. Pharmacogenetics testing allows the clinician to prescribe medications with confidence, by providing information regarding effectiveness and safety for prescription drugs based on an individual’s genetic make-up.